In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Integra Buys IsoTis, Gains Accell Demineralized Bone Matrix In $51 Mil. Deal

This article was originally published in The Gray Sheet

Executive Summary

Closure of Integra LifeSciences' acquisition of orthobiologics firm IsoTis is conditioned upon 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products, Integra says

You may also be interested in...



Integra Issues Delayed 2007 Results, Reports Orthobiologics Integration

Integra Lifesciences is lagging behind in reporting its financial results, but in the meantime has put in place an expanded orthobiologics business

Integra Issues Delayed 2007 Results, Reports Orthobiologics Integration

Integra Lifesciences is lagging behind in reporting its financial results, but in the meantime has put in place an expanded orthobiologics business

IsoTis Accell gains FDA clearance

Integra LifeSciences' pending acquisition of orthobiologics firm IsoTis moves a step closer to completion with the Aug. 15 receipt of 510(k) clearance for IsoTis' Accell line of demineralized bone matrix products. Accell is a key asset of the $51 million deal, which was announced Aug. 7 and conditioned upon Accell market go-ahead. The Accell products are indicated for use as bone graft extenders in the spine, extremities and pelvis, or as bone void fillers in the extremities and pelvis (1"The Gray Sheet" Aug. 13, 2007, p. 10)...

Related Content

UsernamePublicRestriction

Register

MT025127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel